Dawaon ke daam par Supreme Court ka Centre se sawaal — 'system manufacturers ki madad kyun kar raha hai?'; order surakshit
Justice Vikram Nath aur Justice Sandeep Mehta ki bench ne NPPA ko 'totally defunct' kaha aur hospitals mein dawaon par 100–200 guna markup par sawaal uthaye.
Supreme Court ne Mangalvaar ko dawaon ki keemat se jude do petitions par sunvaai ke dauraan Centre se kade sawaal kiye. ANI ki report ke mutabik yachikakarta Kishan Chand Jain ka kehna hai ki lagbhag 82% dawaen DPCO, 2013 ki scheduled category se baahar hain, isliye unki shuruaati keemat tay nahi hoti. Yachika mein non-scheduled dawaon ki keemat ka niyantran, medical devices par price cap aur generic prescription ko anivarya karne ki maang ki gayi hai.
Bench ne National Pharmaceutical Pricing Authority ko 'totally defunct' bataya aur ek udaharan diya jismein retailer Rs 15 mein kharidi drip line Rs 250 mein bechta hai. Justice Mehta ne poocha ki cancer dawaon par profit margin cap karne mein itna samay kyun laga. Hospitals ki taraf se senior advocate Mukul Rohatgi ne infrastructure aur operational kharch ki daleel di, par ANI ke mutabik bench ne kaha ki hospital 'dacoity' ke sahare nahi chal sakte.
Centre ki taraf se ASG Aishwarya Bhati ne kaha ki India mein dawaon ki keemat duniya mein sabse kam mein se hai aur policy ki lagataar samiksha hoti hai. Bench ne jawab diya ki affordability ko desh ki kam per capita income ke hisaab se dekhna hoga. Sunvaai ke baad court ne apna order surakshit rakh liya.